What Are the Fundamentals of NovoCure (NVCR)?

By Blake Campbell • Friday, December 23 12:01 • Permanent Link

NovoCure sank -6.0% today, compared to the S&P 500's day change of 0.3%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:

NovoCure has moved -3.5% over the last year, and the S&P 500 logged a change of -20.2%
NVCR has an average analyst rating of hold and is -18.03% away from its mean target price of $91.5 per share
Its trailing earnings per share (Eps) is $-0.57
NovoCure has a trailing 12 month Price to Earnings (P/E) ratio of -132.3 while the S&P 500 average is 15.97
Its forward earnings per share (Eps) is $-0.99 and its forward P/E ratio is -75.8
The company has a Price to Book (P/B) ratio of 17.7 in contrast to the S&P 500's average ratio of 2.95
NovoCure is part of the Healthcare sector, which has an average P/E ratio of 13.21 and an average P/B of 4.07
The company has a free cash flow of $58,721,248.00, which refers to the total sum of all its inflows and outflows of cash over the last quarter
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.